title: Acetate-free biofiltration versus bicarbonate haemodialysis in the treatment of patients with diabetic nephropathy: a cross-over multicentric study.
abstract: BACKGROUND
  Morbidity and mortality rates in diabetic patients on regular dialysis treatment (RDT) are higher than in non-diabetic-subjects on RDT. Moreover, diabetic patients experience an intradialitic morbidity unacceptably higher than in patients with other causes of terminal renal failure. The aim of the present investigation was to compare standard bicarbonate haemodialysis (BHD) with acetate-free biofiltration (AFB) in a group of 41 diabetic patients stable on dialysis treatment for 25 +/- 22 months.
  
  
  METHODS
  Twenty-four type II and 17 type I diabetic patients, all requiring insulin therapy, were included and were followed for 1 year in a 6-month cross-over randomized study for both methods. The analysis was carried out on dialysis symptoms, interdialysis symptoms, and nutritional status, and the multivariate analysis of variance for repeated measures on the same subjects in the two techniques was used.
  
  
  RESULTS
  AFB significantly reduced dialytic and extradialytic symptoms (P=0.003 and 0.001 respectively). Cardiovascular collapses decreased by 43%, and other dialysis symptoms showed a similar trend (-35%). The interdialysis symptoms decreased by 28% and were accompanied by an increase in subjective wellbeing (39%) when patients were switched from traditional haemodialysis to AFB. Acid base control was better with AFB (P=0.01), both at the beginning and during the session. Slightly significant differences were also obtained for Kt/V (AFB 1.48 +/- 0.29 vs BHD 1.38 +/- 0.30), while no significant difference was noted with respect to sodium mass balance, nutritional status, calorie-protein intake, nPCR, blood glucose profile, and insulin requirements. The number of hospital admissions and the mortality rate, which were much lower during the AFB than the BHD period, were not analysed statistically.
  
  
  CONCLUSIONS
  AFB allows better control of some metabolic aspects, reduces intra- and extradialysis symptoms, and improves patient quality of life. Whether the long-term prognosis can be improved by AFB remains to be established with further studies.
authors.affiliation: Divisione di Nefrologia e Dialisi, Ospedale Maggiore della Carità, Novara, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Verzetti
authors.forename: C
authors.initials: C
authors.lastname: Navino
authors.forename: R
authors.initials: R
authors.lastname: Bolzani
authors.forename: G
authors.initials: G
authors.lastname: Galli
authors.forename: G
authors.initials: G
authors.lastname: Panzetta
mesh_terms: D000085:Acetates; D000328:Adult; D000368:Aged; D001639:Bicarbonates / Q000494:pharmacology*; D018592:Cross-Over Studies; D003928:Diabetic Nephropathies / Q000628:therapy*; D005260:Female; D017583:Hemodiafiltration; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
chemical_list: D000085:Acetates; D001639:Bicarbonates